登录

Mirai Medical任命前波士顿科学高管David A. Pierce为非执行董事

Former Boston Scientific Exec Joins Mirai Medical Board

mpo-mag 等信源发布 2024-03-26 22:52

可切换为仅中文


Mirai Medical has welcomed former Boston Scientific Corp. executive David A. Pierce to its board as a non-executive director.

Mirai Medical欢迎前波士顿科学公司(Boston Scientific Corp.)高管大卫·A·皮尔斯(DavidA.Pierce)出任董事会非执行董事。

“We are thrilled to welcome David to our board. His extensive experience at Boston Scientific, coupled with his deep knowledge of the industry, will undoubtedly play a pivotal role in guiding Mirai Medical's strategic direction,” Mirai Medical CEO Declan Soden, Ph.D., said. “We are confident that Mr.

Mirai Medical首席执行官Declan Soden博士说:“我们很高兴欢迎David加入我们的董事会。他在波士顿科学公司的丰富经验,加上他对该行业的深入了解,无疑将在指导Mirai Medical的战略方向中发挥关键作用。”。“我们相信。

Pierce's contributions will further elevate our capabilities and impact in interventional endoscopy.”.

皮尔斯的贡献将进一步提高我们在介入内窥镜检查方面的能力和影响力。”。

Formerly executive vie president and president of MedSurg, and president of Endoscopy at Boston Scientific, Pierce's career at the medical device firm spanned 31 years. His expertise in product commercialization, market access, and clinical change management in the gastrointestinal endoscopy space positions him as a valuable addition to Mirai Medical's leadership team, according to Mirai Medical.  .

皮尔斯曾任执行副总裁兼MedSurg总裁,波士顿科学公司内窥镜检查总裁,在这家医疗器械公司工作了31年。据Mirai Medical称,他在胃肠道内窥镜检查领域的产品商业化,市场准入和临床变革管理方面的专业知识使他成为Mirai Medical领导团队的宝贵补充。(笑声)。。

“I am honoured to be part of Mirai Medical, a company at the forefront of innovation in interventional endoscopy. The mission to enable every endoscopist to treat at diagnosis resonates strongly with me, and I look forward to contributing to the company's growth and success,” Pierce stated.

皮尔斯表示:“我很荣幸能成为米莱医疗(Mirai Medical)的一员,这是一家在介入内窥镜检查领域处于创新前沿的公司。让每一位内镜医师在诊断时都能进行治疗的使命与我产生了强烈的共鸣,我期待着为公司的发展和成功做出贡献。”。

Mirai Medical is a medtech start-up specializing in pulsed field ablation within the gastrointestinal tract. It aims to empower every endoscopist to treat at diagnosis. The company's proprietary ePORE therapy is designed with precise algorithmic control of PFA parameters enabling the safe and effective treatment of both pre-malignant and malignant disease across the entire gastrointestinal tract.

Mirai Medical是一家医疗技术初创公司,专门从事胃肠道内的脉冲场消融。它旨在使每位内镜医师能够在诊断时进行治疗。该公司专有的ePORE疗法的设计具有对PFA参数的精确算法控制,可以安全有效地治疗整个胃肠道的恶变前和恶性疾病。

Mirai Medical are headquartered in Galway, Ireland.  .

Mirai Medical总部位于爱尔兰戈尔韦。。